NICE guidance published today recommends leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

Our highly specialised technologies (HST) programme is designed specifically to evaluate technologies for ultra-rare, debilitating conditions. It helps encourage research and innovation in areas where ...

While annual physical checks already take place for people with long-term conditions, we've found that BMI and waist-to-height measurements aren't consistently recorded. Our new approach addresses ...

A list of downloadable documents created during development.

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is ...

A list of downloadable documents created during development.

Tools to help you put the guidance into practice.

Today we’ve published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab. Our independent committee said last year that the ...